PRECISIONNCT07924722
Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Radiological fracture healing status at Week 18 assessed by CT
Timeframe: From enrollment to week 18 after surgery
Secondary (8)
Radiological assessment of fracture healing at week 18, and 36 post-surgery (RUSH)
Radiological assessment of fracture healing at week 18, and 36 post-surgery (mRUST)
Radiological assessment of fracture healing at week 18, and 36 post-surgery (2D binary)
Improvement of pain at week 6, 18, 36, and 52, assessed by VAS pain scores
Improvement of health-related quality of life at week 6, 18, 36, and 52, assessed by EQ-5D-5L
Show 3 moreShow less
Improvement physical function at week 6, 18, 36, and 52, assessed by SMFA
Return-to-work at week 6, 18, 36, and 52
Incidence, severity, and relationship of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE (Version Number V6.0))
Arms and interventions
Treatment ArmExperimental
Iloprost
Control ArmPlacebo comparator
Normal saline (0.9% NaCl)
Drugs: Ilomedin
Other: Normal saline placebo